Industry landscapes
The companies, capital and talent shaping healthtech in Canada. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
234 of 3,570 tracked companies have open roles.
549 of 3,570 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 913 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 23.1% of disclosed capital, while 84.6% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $226.78M | 195 | 49 |
| 2017 | $484.42M | 194 | 68 |
| 2018 | $509.44M | 240 | 72 |
| 2019 | $949.57M | 271 | 80 |
| 2020 | $641.77M | 361 | 82 |
| 2021 | $1.1B | 188 | 84 |
| 2022 | $364.7M | 154 | 70 |
| 2023 | $324.37M | 106 | 58 |
| 2024 | $720.55M | 74 | 58 |
| 2025 | $700.44M | 9 | 74 |
Share of all disclosed company funding.
1,128 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by Ontario Canada.
Backed by Ontario Canada.
Backed by .
Backed by .
Backed by M Ventures and Whitecap Venture Partners and others.
Backed by Wittington Ventures and Continuum Health Ventures and others.
Backed by Graphite Ventures and MaRS IAF and others.
Backed by Brightspark Ventures and Diagram Ventures and others.
Backed by Janus Henderson Investors and Qatar Investment Authority and others.
Backed by Generation Investment Management and Inovia Capital and others.
Backed by Fidelity Investments and T. Rowe Price.
Backed by Guoxin Capital and SBCVC and others.
Backed by Fidelity Investments and Durable Capital Partners.
Backed by MedVenture Partners.
Backed by MedVenture Partners.
Backed by Peloton Capital Management.
Backed by Shoppers Drug Mart Corporation.
Participating investors were not recorded in this snapshot.
The measured Canada identity-to-filing probe did not produce a qualifying designated legal or national-ID join: world_filings_distributed exposes no reviewed Canadian national-ID key; none of the designated Canadian identities carried a CIK.
How the Canada companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
37 of the 3,571 companies on this page carry a measured traffic record (1%); these are the largest of those, by monthly visits. The median among them is 260,621 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| PointClickCarepointclickcare.com | 4,905,539 | 61 | 33.2% |
| CognisantMDcognisantmd.com | 1,817,777 | 36 | 71% |
| Well.cawell.ca | 1,527,027 | 48 | 69.1% |
| GOrendezvousgorendezvous.com | 1,040,067 | 40 | 80% |
| Familiprixfamiliprix.com | 905,692 | 54 | 77.4% |
| Practice Betterpracticebetter.io | 878,840 | 38 | 32% |
| RateMDsratemds.com | 784,760 | 52 | 62.2% |
| Wibbiwibbi.com | 757,828 | 35 | 62% |
| Medeomedeohealth.com | 575,106 | 40 | 66.5% |
| InputHealthinputhealth.com | 540,617 | 32 | 57.7% |
Visits and authority are third-party web estimates, not company-reported figures.
344 of these companies (9.6%) publish at least one Android app — 481 apps in all, carrying 63.1M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| BetterSleep: Sleep trackerBetterSleep | 24.9M | 4.4 | Health & Fitness |
| Pregnancy AppAmila | 9.8M | 4.9 | Parenting |
| Baby tracker - feeding, sleepAmila | 3.2M | 4.9 | Parenting |
| Rootd - Anxiety & Panic ReliefRootd | 2.7M | 4.4 | Health & Fitness |
| Figure 1 - Medical CasesFigure 1 | 2.2M | 4.1 | Medical |
| Fertility Friend Ovulation AppFertility Friend | 1.9M | 4.6 | Health & Fitness |
| Staying AliveStaying Alive | 1.7M | 3.4 | Medical |
| PC HealthPC Health | 1.3M | 3.9 | Medical |
| Breethe - Sleep & MeditationBreethe | 1.3M | 4.6 | Health & Fitness |
| Maple on-demand healthcareMaple | 911.3K | 4.2 | Medical |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2024Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Disease Self Management | 182 | 50M | BetterSleep: Sleep tracker 24.9M | |
| Fitness & Wellness Tech | 72 | 33.7M | Rootd - Anxiety & Panic Relief 2.7M | |
| Healthcare It | 257 | 7.7M | Figure 1 - Medical Cases 2.2M | |
| Healthcare Booking Platforms | 59 | 4.8M | PC Health 1.3M | |
| Continued Learning | 4 | 2.4M | UBC Radiology 143.8K | |
| Wearable Technology | 53 | 1.2M | Unitron Remote Plus 572K | |
| Local Services | 7 | 1.1M | Maple on-demand healthcare 911.3K | |
| Assistive Tech | 10 | 750K | Sentinare Activity Sensor 176.6K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 400 of 481 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
144 companies hiring · $6.19B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Nervonik has now raised a total of $65.5M in total equity funding and is backed by Amzak Health Investors, Elevage Medical Technologies, Foothill Ventures, Lumira Ventures, Shangbay Capital, and U.S. Venture Partners.
Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) announces that it proposes to complete a private placement (the “Offering”) of up to 2,800,000 units of the Corporation (“Units”) at a price of $0.55 per Unit for gross proceeds of up to $1,540,000.
ViewsML raised $4.9M seed round for virtual biomarker staining.
PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL3) is pleased to announce that it has entered into a non-binding Letter of Intent (the “LOI”) dated April 13, 2026 with Ayla BioScience Inc. (“Ayla BioScience”), whereby the Company will acquire all of the issued and outstanding common shares of Ayla BioScience (the “Proposed Transaction”).
The Corporation issued an aggregate of 6,404,700 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,665,222.
Organon decided to sell its JADA post-partum haemorrhage (PPH) treatment system to Laborie Medical for up to $465 million.
Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the successful completion by affiliates of Madryn Asset Management, LP (“Madryn”) of a short-form merger transaction, pursuant to which 100% ownership of the Company’s common stock is now consolidated under funds managed by Madryn (the “Short-form Merger”).
AI/ML Innovations Inc. (" AIML " or the " Company ") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement (the " Offering ")
Respan has now raised a total of $5.5M in total equity funding and is backed by Alpen Capital, Antigravity Capital, Gradient, Hat-Trick Capital, XiaoXiao Fund, and Y Combinator.
RevSpring, a Frazier Healthcare Partners portfolio company, has acquired TrustCommerce®, a portfolio company of Waud Capital Partners and a leading provider of end-to-end integrated healthcare payment and security solutions.
Top 10 categories among 837 recorded events in the 24-month window.
6 companies with recorded IPO activity
IPO activity · OTCQB1 reports
Follow-on Offering · TSX2 reports
Follow-on Offering · TSX Venture Exchange2 reports
IPO · U.S.1 reports
IPO · Nasdaq1 reports
Follow-on Offering · Nasdaq1 reports
29 tracked people moves
Resignation Previously Founder
Appointment Board of Directors
Promotion SVP & Head of Venues
Resignation Previously Auditor of American Aires Inc.
Resignation Previously Auditor
Appointment Vice President, Head of Sponsorships
Appointment Senior Vice President of Data Solutions
Appointment Head/venue marketing
Products, platforms and features in the recorded window
Hormone test
Hormone test
Feature
Healthcare AI Platform
18 recorded customer wins
Customer: horizon healthMedical Devices
Customer: Healthcare
Customer: State Health System
Customer: campfire
Customer: Province of OntarioLife Sciences
Customer: canada health infowayHealthcare
1 companies with reported reductions
105 rolesbusiness downturn
41 recorded events
submitted for approvalChina\'s National Medical Products Administration
approvedUS FDA
approved for issuing shares to satisfy interest payment obligationsTSX Venture Exchange
Device sales halted in Canada due to expired licenceHealth Canada
5 tracked suits
alleged misconduct and related matters · Ongoing
alleged misconduct by former officersCivil · Ongoing
Reported company results in the recorded window.
Median across 81 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| ge healthcare→Intelerad ↗ | Announced | 2026-04-15 | $2.3B |
| PanGenomic→Ayla BioScience Inc. | Announced | 2026-04-14 | Not stated in snapshot |
| Laborie Medical→organon | 2026-04-10 | $465.0M | |
| Laborie Medical→JADA post-partum haemorrhage treatment system | Completed | 2026-04-10 | $465.0M |
| madryn asset management→venus concept ↗ | Completed | 2026-03-30 | Not stated in snapshot |
| RevSpring→trustcommerce | Announced | 2026-03-09 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
2,481 postings in the preceding 12 months. The full 7,229-posting snapshot covers 218 employers.
116 tracked postings mention remote work.
1,325 postings specify a level.
Top skills across 7,229 tracked postings in the available jobs snapshot.
Median across 805 postings with pay data, expressed in USD.
Advertised posting medians do not describe all employees or roles.
| Company | Open roles |
|---|---|
| RhynoCare ↗ | 11 |
| Amico ↗ | 11 |
| WELL Health Technologies Corp ↗ | 11 |
| Brunet ↗ | 10 |
| Petal ↗ | 10 |
| CARE Group ↗ | 9 |
| Phoenix ↗ | 9 |
| Dialogue ↗ | 9 |
| Company | Employees |
|---|---|
| Patterson Dental ↗ | 6,772 |
| 123Dentist ↗ | 5,000 |
| WELL Health Technologies Corp ↗ | 1,710 |
| Familiprix ↗ | 1,586 |
| pt Health ↗ | 1,001 |
| PointClickCare ↗ | 742 |
| venus concept ↗ | 384 |
| Stenberg College ↗ | 381 |
1,621 founders and chief executives across 1,231 companies.
Ex- PayPal, CEO TIO Networks . University of British Columbia
Ex-Creo Angel Investor.Stanford University Graduate School of Business MBA 1981.
TrackTik, Resolver, Schauer Ventures, ChipCare, Madiro, ex-JDA Software, CEO Vortex Connect, Rogers Wireless. Queens University BEng 2001…
Western University BSc 1994
Ex-ABK Biomedical, Ellex, President and CEO ReShape Medical. Saint Joseph's University BS, Marketing 1992
Tela Bio, ex-Vesper Medical, ex-Intact Vascular, university of pennsylvania, 1970
University of Toronto PhD 2008
Ex-Hologic, Sentinelle Medical · University of Waterloo BASc 1998, University of Toronto MS 2001
Co-Founder Asiri Skincare, ex-CEO Endo International, Bausch Health Companies, Novartis, McKinsey & Company. Princeton University BSE 1989…
Bioworld Ventures, Verge HealthTech Fund, ex-Genesis Medtech Group. Duke University BS
Spineology, ex-Alphatec Spine, ex-Nuvasive, Duke University - The Fuqua School of Business, 2008
Felix Health, ex-500px, ex-Origin Merchant Partners, University of St Andrews, 2011
323 profiles with education records.
23 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
1,355,275 articles in the measured 12-month window.
Healthtech coverage across Canada · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 366,209 |
| 2021Q3 | 377,994 |
| 2021Q4 | 376,921 |
| 2022Q1 | 394,619 |
| 2022Q2 | 389,460 |
| 2022Q3 | 408,113 |
| 2022Q4 | 456,720 |
| 2023Q1 | 470,776 |
| 2023Q2 | 460,917 |
| 2023Q3 | 419,360 |
| 2023Q4 | 365,769 |
| 2024Q1 | 368,649 |
| 2024Q2 | 357,992 |
| 2024Q3 | 331,166 |
| 2024Q4 | 344,801 |
| 2025Q1 | 539,170 |
| 2025Q2 | 330,874 |
| 2025Q3 | 882,639 |
| 2025Q4 | 131,411 |
| 2026Q1 | 178,944 |
Article volume measures coverage, not market sales.
1,184 recorded company events across 139 companies; percentages use that event total.
Healthtech coverage across Canada · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Healthtech coverage across Canada
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| multilateral diplomacy | 1,066 | 722 | 48% |
| angel investors | 1,034 | 401 | 158% |
| ice sports | 874 | 229 | 282% |
| international cups | 817 | 575 | 42% |
| investment deal | 780 | 443 | 76% |
| wto rulings | 756 | 393 | 92% |
| national security strategy | 623 | 386 | 61% |
| share price | 617 | 431 | 43% |
| cannabis policy reform discussions | 587 | 354 | 66% |
| international cooperation | 571 | 386 | 48% |
| tariff negotiations | 6,293 | 15,282 | -59% |
| free trade deals | 3,129 | 6,377 | -51% |
| trade dispute mechanisms | 2,928 | 4,662 | -37% |
| bilateral trade | 1,917 | 3,505 | -45% |
| preferential tariff | 1,286 | 3,313 | -61% |
Healthtech coverage across Canada
tariff negotiations, free trade deals, trade dispute mechanisms
37.0% critical · 35.1% positiveangel investors, investment deal, trade deficits fx
29.0% critical · 42.5% positiveleague expansion news, earnings report, quarterly financials
27.0% critical · 46.7% positiveHealthtech coverage across Canada. Topic labels describe recorded classifications and can include broad context.
53,214 papers in the recorded worldwide scope.
Tone counts: 46,301 positive · 2,052 neutral · 4,861 negative.
Landmark: Implementation strategies: recommendations for specifying and reporting
Landmark: Deep Learning for Health Informatics
Landmark: Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
Common problems researchers identify · 0119.0% of this theme group
Health informatics (400) · Health administration (281) · Nursing research (250) · Public health (273)
Resilient Health Care: a systematic review of conceptualisations, study methods and factors that develop resilience
Health systems resilience in practice: a scoping review to identify strategies for building resilience
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Common problems researchers identify · 0218.9% of this theme group
Drug discovery (321) · Drug (197) · Drug development (103) · Disease (155)
A perspective on multi‐target drug discovery and design for complex diseases
Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
| Year | Share index |
|---|---|
| 2022 | 157.3 |
| 2023 | 161.8 |
| 2024 | 169.7 |
| 2025 | 211.5 |
Common problems researchers identify · 0315.9% of this theme group
Digital health (627) · Health care (357) · Digital transformation (69) · eHealth (97)
Technology and Universal Health Coverage: Examining the role of digital health
Engagement With and Acceptability of Digital Media Platforms for Use in Improving Health Behaviors Among Vulnerable Families: Systematic Rev
| Year | Share index |
|---|---|
| 2022 | 538.7 |
| 2023 | 553.0 |
| 2024 | 540.4 |
| 2025 | 843.9 |
Common problems researchers identify · 0414.7% of this theme group
Telemedicine (604) · Telehealth (394) · Health care (334) · Telerehabilitation (53)
Opportunities and challenges for telehealth within, and beyond, a pandemic
Strategies for Evaluating Telehealth
| Year | Share index |
|---|---|
| 2022 | 542.2 |
| 2023 | 554.7 |
| 2024 | 541.1 |
| 2025 | 844.0 |
Common problems researchers identify · 0511.7% of this theme group
Precision medicine (480) · Personalized medicine (238) · Disease (116) · Precision oncology (28)
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Personalizing Oncology: Perspectives and Prospects
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Common problems researchers identify · 0610.9% of this theme group
Medical device (221) · Wearable computer (50) · Medical equipment (27) · Risk analysis (34)
Energy sources and their development for application in medical devices
Medical Devices and Health — Creating a New Regulatory Framework for Moderate-Risk Devices
| Year | Share index |
|---|---|
| 2022 | 40.4 |
| 2023 | 42.2 |
| 2024 | 43.7 |
| 2025 | 72.1 |
Common problems researchers identify · 078.8% of this theme group
Pandemic (394) · Coronavirus disease 2019 (274) · 2019-20 coronavirus outbreak (69) · Telemedicine (258)
Quantifying the Impact of COVID-19 on Telemedicine Utilization: Retrospective Observational Study
Telemedicine Evaluations in Neuro-Ophthalmology During the COVID-19 Pandemic: Patient and Physician Surveys
| Year | Share index |
|---|---|
| 2022 | 655.3 |
| 2023 | 440.6 |
| 2024 | 327.7 |
| 2025 | 212.1 |
Cautions · 0119.8% of this theme group
Telemedicine (762) · Telehealth (476) · Telerehabilitation (118) · Health care (319)
The Role of Telemedicine in Improving Healthcare Outcome: A Review
Assessing the Efficiency and Patient Satisfaction of Telemedicine in Managing Chronic Health Conditions
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Cautions · 0219.8% of this theme group
Health informatics (239) · Health administration (157) · Nursing research (113) · Medical device (92)
Challenges of using e-health technologies to support clinical care in rural Africa: a longitudinal mixed methods study exploring primary hea
Development and analysis of quality assessment tools for different types of patient information – websites, decision aids, question prompt l
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Cautions · 0315.3% of this theme group
Drug discovery (202) · Drug (160) · Pharmacogenomics (109) · Pharmacogenetics (64)
Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape
Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologic
| Year | Share index |
|---|---|
| 2022 | 154.6 |
| 2023 | 158.9 |
| 2024 | 165.9 |
| 2025 | 206.7 |
Cautions · 0414.7% of this theme group
Digital health (480) · Psychological intervention (265) · Mental health (159) · Health care (262)
Digital Health Interventions to Enhance Prevention in Primary Care: Scoping Review
Digital Health Interventions for Promoting Healthy Aging: A Systematic Review of Adoption Patterns, Efficacy, and User Experience
| Year | Share index |
|---|---|
| 2022 | 790.2 |
| 2023 | 807.5 |
| 2024 | 810.9 |
| 2025 | 1159.7 |
Cautions · 0511.2% of this theme group
Pandemic (431) · Coronavirus disease 2019 (360) · Telemedicine (348) · 2019-20 coronavirus outbreak (77)
Community Mental Health Clinicians’ Perspectives on Telehealth During the COVID-19 Pandemic: Mixed Methods Study
Exploring Ophthalmologists’ Adoption of Telemedicine during the COVID-19 Pandemic: A Mixed Methods Study
| Year | Share index |
|---|---|
| 2022 | 544.1 |
| 2023 | 376.7 |
| 2024 | 243.3 |
| 2025 | 191.2 |
Cautions · 0610.3% of this theme group
Precision medicine (249) · Personalized medicine (164) · Cancer (103) · Oncology (57)
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Sur
Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy—A Narrative Review
| Year | Share index |
|---|---|
| 2022 | 767.8 |
| 2023 | 1043.6 |
| 2024 | 798.0 |
| 2025 | 771.4 |
Cautions · 078.8% of this theme group
Applications of artificial intelligence (102) · Transformative learning (77) · Health care (188) · Precision medicine (102)
Artificial intelligence in healthcare: revolutionizing precision medicine, predictive analytics, and ethical considerations in autonomous di
Artificial Intelligence in Medicine: Transforming Diagnosis, Treatment, and Healthcare Delivery
| Year | Share index |
|---|---|
| 2022 | 534.7 |
| 2023 | 549.6 |
| 2024 | 538.1 |
| 2025 | 839.2 |
Opportunities · 0118.0% of this theme group
Digital health (282) · Health care (348) · Health informatics (142) · Psychological intervention (156)
Development of an Evidence-Based Conceptual Model of the Health Care Sector Under Digital Transformation: Integrative Review
HCI-modelling for improving the clinical usability of digital health technologies
| Year | Share index |
|---|---|
| 2022 | 541.3 |
| 2023 | 554.6 |
| 2024 | 543.2 |
| 2025 | 853.3 |
Opportunities · 0216.6% of this theme group
Drug discovery (282) · In silico (99) · Drug (156) · Docking (85)
Exploring Cimetidine\nas a Potential Therapeutic Attenuator\nagainst Amyloid Formation in Parkinson’s Disease: Spectroscopic\nand Microscopi
Design, Synthesis,\nand Biological Evaluation of 5‑Formyl-pyrrolo[3,2‑<i>b</i>]pyridine-3-carboxamides as New Selective, Potent,
| Year | Share index |
|---|---|
| 2022 | 167.5 |
| 2023 | 172.4 |
| 2024 | 180.4 |
| 2025 | 218.9 |
Opportunities · 0313.8% of this theme group
Drug discovery (535) · Computational biology (222) · Drug (223) · Chemical space (66)
Assessing molecular docking tools: understanding drug discovery and design
Molecular Docking in Computer-Aided Drug Discovery: A Powerful Tool for Targeted Therapeutics
| Year | Share index |
|---|---|
| 2022 | 281.3 |
| 2023 | 298.1 |
| 2024 | 330.7 |
| 2025 | 367.6 |
Opportunities · 0413.7% of this theme group
Telemedicine (475) · Telehealth (353) · Telerehabilitation (87) · Physical therapy (75)
Urgent and non-emergent telehealth care for seniors: Findings from a multi-site impact study
Telehealth for the study of palliative care communication: opportunities, methodological challenges, and recommendations
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Opportunities · 0512.7% of this theme group
Precision medicine (283) · Personalized medicine (216) · Disease (142) · Pharmacogenomics (61)
Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease
Deep Learning for Precision Medicine: Advancing Personalized Treatment Plans in Oncology
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Opportunities · 0612.7% of this theme group
Wearable computer (117) · Medical device (84) · Remote patient monitoring (76) · Internet of Things (49)
Wearable technology. Health-care solutions for a growing global population.
IoT Based Effective Wearable Healthcare Monitoring System For Remote Areas
| Year | Share index |
|---|---|
| 2022 | 40.5 |
| 2023 | 42.2 |
| 2024 | 44.3 |
| 2025 | 74.3 |
Opportunities · 0712.5% of this theme group
Cancer (241) · Precision medicine (207) · Breast cancer (90) · Lung cancer (44)
Bioinformatics-Based Analysis of Circulating Tumor Cells: A Methodological Overview of Personalized Cancer Treatment
[Molecular biomarkers in breast cancer : advances in precision medicine].
| Year | Share index |
|---|---|
| 2022 | 776.6 |
| 2023 | 1055.1 |
| 2024 | 810.2 |
| 2025 | 787.3 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 29.7% | 37.8% |
| Problem-identifying | 29.0% | 9.5% |
| Descriptive | 18.8% | 17.4% |
| Breakthrough | 12.7% | 25.9% |
| Cautionary | 6.4% | 4.6% |
| Comparative | 2.5% | 3.8% |
| Critical | 0.9% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceThe future of digital health with federated learning | 4,573 | 2.66% | 2,251 (49.2%) | 2.66% |
| Safety & misuseImpact of Rumors and Misinformation on COVID-19 in Social Media | 292 | 0.17% | 167 (57.2%) | 0.17% |
| Bias & fairnessChallenges and recommendations for wearable devices in digital health: Data quality, interoperability, health equity, fa | 99 | 0.06% | 45 (45.5%) | 0.06% |
| Hardware, e-waste & supply chainE-waste for health: recycling smartphones for health monitoring | 24 | 0.01% | 7 (29.2%) | 0.01% |
| Concentration of compute powerDemonopolizing Medical Knowledge | 16 | 0.01% | 7 (43.8%) | 0.01% |
| Labour & data workNew Work—New Interventions: Digital Occupational Health Interventions and the Co-Creation of a Human-Centered Future of | 11 | 0.01% | 6 (54.5%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 10 | 0.01% | 4 (40.0%) | 0.01% |
| Carbon & emissions of computeSustainable AI-Enabled UAV Healthcare Logistics: Environmental, Social, and Governance Implications from a PRISMA-ScR Re | 3 | 0.0% | 1 (33.3%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Published patent filings in the recorded source window.
Compare demand signals in Canada’s newsflow with the healthtech categories mapped to each signal.
Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.
The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.
Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.
Swipe horizontally to compare all columns →
| Signal family | Signal percentile | Supply percentile | Relative gap | Gap (points) | Signal share vs prior year |
|---|---|---|---|---|---|
| Mental health ↗Disease Burden | 58.3 | 0.0 | +58.3 | +37.2% | |
| Infectious outbreaks ↗Disease Burden | 66.7 | 62.5 | +4.2 | +95.2% | |
| Ageing & elder care ↗Disease Burden | 8.3 | 25.0 | -16.7 | +5.4% | |
| Air pollution ↗Environmental Driver | 41.7 | 62.5 | -20.8 | +60.3% | |
| Cancer burden ↗Disease Burden | 25.0 | 100.0 | -75.0 | -23.5% | |
| Maternal & child health ↗Disease Burden | 83.3 | — | No matching category | — | +74.4% |
| Layoffs & income shocks ↗Spending Pressure | 66.7 | — | No matching category | — | +20.9% |
Showing all 7 signals. Select a family for its history and mapped categories.
All 9 city readings for these demand families in the comparison geography. Canada is highlighted.
Each city’s reading is a share of its own coverage.
Maternal & child health · Mental health · Infectious outbreaks
Maternal & child health · Mental health · Layoffs & income shocks
Mental health · Maternal & child health · Cancer burden
Layoffs & income shocks · Cancer burden · Mental health
Ageing & elder care · Maternal & child health · Infectious outbreaks
Maternal & child health · Mental health · Air pollution
Mental health · Infectious outbreaks · Maternal & child health
Maternal & child health · Layoffs & income shocks · Mental health
Layoffs & income shocks · Mental health · Air pollution
Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 62 | 8.82 |
| 2024Q4 | 51 | 6.79 |
| 2025Q1 | 40 | 4.1 |
| 2025Q2 | 88 | 13.49 |
| 2025Q3 | 89 | 6.93 |
| 2025Q4 | 54 | 13.07 |
| 2026Q1 | 68 | 14.15 |
Outbreak pressure can pull testing, surveillance and rapid-care demand at short notice.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 21 | 2.99 |
| 2024Q4 | 29 | 3.86 |
| 2025Q1 | 29 | 2.97 |
| 2025Q2 | 21 | 3.22 |
| 2025Q3 | 67 | 5.22 |
| 2025Q4 | 45 | 10.89 |
| 2026Q1 | 30 | 6.24 |
An ageing base can shift demand toward geriatric, home and chronic care.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 39 | 5.55 |
| 2024Q4 | 50 | 6.66 |
| 2025Q1 | 33 | 3.38 |
| 2025Q2 | 34 | 5.21 |
| 2025Q3 | 44 | 3.43 |
| 2025Q4 | 24 | 5.81 |
| 2026Q1 | 44 | 9.15 |
Sustained air-quality stress can pull respiratory and cardiac care demand with it.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 43 | 6.12 |
| 2024Q4 | 19 | 2.53 |
| 2025Q1 | 44 | 4.51 |
| 2025Q2 | 26 | 3.99 |
| 2025Q3 | 115 | 8.96 |
| 2025Q4 | 30 | 7.26 |
| 2026Q1 | 14 | 2.91 |
Cancer burden can pull screening, diagnostics and oncology capacity demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 77 | 10.96 |
| 2024Q4 | 84 | 11.19 |
| 2025Q1 | 85 | 8.71 |
| 2025Q2 | 41 | 6.29 |
| 2025Q3 | 78 | 6.08 |
| 2025Q4 | 38 | 9.2 |
| 2026Q1 | 31 | 6.45 |
Maternal and child burden can pull immunisation, nutrition and pediatric care demand.
This signal has no matching category in the page’s healthtech market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 79 | 11.24 |
| 2024Q4 | 84 | 11.19 |
| 2025Q1 | 75 | 7.68 |
| 2025Q2 | 65 | 9.97 |
| 2025Q3 | 223 | 17.37 |
| 2025Q4 | 49 | 11.86 |
| 2026Q1 | 68 | 14.15 |
Layoff cycles can pull discretionary spend back toward value offerings.
This signal has no matching category in the page’s healthtech market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 116 | 16.51 |
| 2024Q4 | 107 | 14.25 |
| 2025Q1 | 135 | 13.83 |
| 2025Q2 | 93 | 14.26 |
| 2025Q3 | 160 | 12.46 |
| 2025Q4 | 93 | 22.51 |
| 2026Q1 | 111 | 23.09 |
Canada healthtech coverage
Bipolar Disorders
1,710 citations in the snapshot
Health Research Policy and Systems
500 citations in the snapshot
European Heart Journal
421 citations in the snapshot
Eurosurveillance
410 citations in the snapshot
Canada coverage of this page's demand families
| Keyword | Recent articles | Prior articles | Share change |
|---|---|---|---|
| provider vaccine recommendations | 65 | 21 | 258.7% |
| cdc vaccination calendar | 75 | 29 | 199.7% |
| catch-up immunization schedule | 57 | 24 | 175.2% |
| air quality standards | 45 | 51 | 2.2% |
| support groups cancer | 40 | 62 | -25.2% |
Share changes describe coverage in the stated comparison periods, not search demand or market size.
Company counts, hiring and disclosed funding across the recorded hubs.
41.9% across the displayed hubs
63 companies hiring · $2.4B disclosed funding
Explore companies in Toronto ↗
18.1% across the displayed hubs
27 companies hiring · $1.3B disclosed funding
Explore companies in Vancouver ↗
13.8% across the displayed hubs
20 companies hiring · $436.1M disclosed funding
Explore companies in Montreal ↗
7.7% across the displayed hubs
5 companies hiring · $126.9M disclosed funding
Explore companies in Calgary ↗
5.4% across the displayed hubs
9 companies hiring · $579.8M disclosed funding
Explore companies in Mississauga ↗
4.8% across the displayed hubs
2 companies hiring · $81.7M disclosed funding
Explore companies in Ottawa ↗
4.5% across the displayed hubs
9 companies hiring · $15.3M disclosed funding
Explore companies in Edmonton ↗
3.8% across the displayed hubs
4 companies hiring · $137.5M disclosed funding
Explore companies in Surrey ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗